RSLS Overview

Merger Announcement: Vyome Therapeutics has completed its merger with ReShape Lifesciences, and the new entity will operate under the name Vyome Holdings, Inc. starting August 15, 2025, with the trading symbol "HIND."

Company Focus and Future Outlook: Vyome aims to leverage its clinical-stage assets to address immuno-inflammatory conditions while maintaining a cost-efficient operation across the US-India innovation corridor, although future performance is subject to uncertainties and risks.

Penny Stocks to Watch: Momentus, X4 Pharmaceuticals, and ReShape Lifesciences are highlighted as top penny stocks based on their significant Dollar Volume and recent stock price surges, with Momentus experiencing a 72% increase after a NASA contract announcement.

Company Developments: X4 Pharmaceuticals secured an $85 million private placement to support its drug development, while ReShape Lifesciences' shares rose 57.6% following the approval of its merger with Vyome Therapeutics, set to trade under a new name.

Merger and Nasdaq Listing: Vyome Therapeutics, Inc. will officially list on the Nasdaq under the name Vyome Holdings, Inc. with the ticker symbol "HIND" following its merger with ReShape Lifesciences, effective August 15, 2025.

Focus on Immuno-inflammatory Conditions: The company aims to address significant unmet needs in the immuno-inflammatory disease market, which exceeds $100 billion, leveraging its clinical-stage assets and innovative approaches in healthcare.

Vyome's Board Transition: Vyome Therapeutics, Inc. is set to take control of ReShape Lifesciences on August 15, 2025, with a new board comprised of experienced professionals, including MIT alumni, focused on aligning with shareholder interests and leveraging AI in healthcare.

Company Vision and Goals: Vyome aims to transform the lives of patients with immuno-inflammatory conditions while maintaining a cost-efficient operation and high standards of quality and safety, as it prepares for its public listing under the ticker 'HIND' following a reverse merger.

Special Meeting of Stockholders: ReShape Lifesciences partially adjourned its Special Meeting to gather more votes for the Asset Sale Proposal and Charter Amendment Proposal, which are essential for completing a merger with Vyome Therapeutics.

Voting Encouragement: Stockholders are urged to vote in favor of these proposals by August 7, 2025, as their approval is crucial for maximizing shareholder value and ensuring the operational success of the merged entity.

Merger and Asset Sale Announcement: ReShape Lifesciences' Board of Directors has unanimously recommended a merger with Vyome Therapeutics and the sale of its assets to Biorad Medisys, urging shareholders to vote in favor of the proposals at a special meeting on July 24, 2025.

Strategic Growth Potential: The merger aims to enhance the development of immune-inflammatory therapies and leverage opportunities between the U.S. and India, with both companies expressing optimism about maximizing shareholder value through these transactions.